Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 3
1995 9
1996 23
1997 40
1998 50
1999 71
2000 82
2001 98
2002 85
2003 70
2004 94
2005 98
2006 51
2007 51
2008 57
2009 65
2010 75
2011 88
2012 102
2013 100
2014 113
2015 111
2016 126
2017 104
2018 115
2019 119
2020 145
2021 168
2022 132
2023 138
2024 124
2025 157
2026 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,560 results

Results by year

Filters applied: . Clear all
Page 1
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, Cheng S, Sun XJ, Liu F, Huang JY, Ji MM, Zhao WL. Huang YH, et al. Signal Transduct Target Ther. 2021 Jan 11;6(1):10. doi: 10.1038/s41392-020-00437-8. Signal Transduct Target Ther. 2021. PMID: 33431788 Free PMC article.
Among all 619 DLBCL patients, somatic mutations in KMT2D (19.5%) were most frequently observed, followed by mutations in ARID1A (8.7%), CREBBP (8.4%), KMT2C (8.2%), TET2 (7.8%), EP300 (6.8%), and EZH2 (2.9%). Among them, CREBBP/EP300 mutations were significantly ass …
Among all 619 DLBCL patients, somatic mutations in KMT2D (19.5%) were most frequently observed, followed by mutations in ARID1A (8.7%), C …
CREBBP and p300 lysine acetyl transferases in the DNA damage response.
Dutto I, Scalera C, Prosperi E. Dutto I, et al. Cell Mol Life Sci. 2018 Apr;75(8):1325-1338. doi: 10.1007/s00018-017-2717-4. Epub 2017 Nov 23. Cell Mol Life Sci. 2018. PMID: 29170789 Free PMC article. Review.
The CREB-binding protein (CREBBP, or in short CBP) and p300 are lysine (K) acetyl transferases (KAT) belonging to the KAT3 family of proteins known to modify histones, as well as non-histone proteins, thereby regulating chromatin accessibility and transcription. ...
The CREB-binding protein (CREBBP, or in short CBP) and p300 are lysine (K) acetyl transferases (KAT) belonging to the KAT3 family of …
CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition.
Garcia-Gimenez A, Ditcham JE, Azazi DMA, Giotopoulos G, Asby R, Meduri E, Bagri J, Sakakini N, Lopez CK, Narayan N, Beinortas T, Agrawal-Singh S, Fung K, O'Connor D, Mansour MR, Alabed HBR, Jenkins B, Koulman A, Murphy MP, Horton SJ, Huntly BJP, Richardson SE. Garcia-Gimenez A, et al. Nat Commun. 2025 May 20;16(1):4274. doi: 10.1038/s41467-025-59531-6. Nat Commun. 2025. PMID: 40393984 Free PMC article.
Mutations in the histone acetyltransferase CREBBP confer high-risk and increased chemoresistance in ALL. Performing a targeted drug-screen in isogenic human cell lines, we identify a number of small molecules that specifically target CREBBP-mutated B-ALL, the most p …
Mutations in the histone acetyltransferase CREBBP confer high-risk and increased chemoresistance in ALL. Performing a targeted drug-s …
CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.
Kumar EA, Korfi K, Bewicke-Copley F, Close K, Heward J, Witzig T, Leukam M, Ansell S, Scott J, Clear A, Efeyan A, Green M, Siebert R, Peck B, Calaminici M, Wang J, Smith S, Novak A, Fitzgibbon J, Okosun J. Kumar EA, et al. Br J Haematol. 2024 Nov;205(5):1804-1809. doi: 10.1111/bjh.19671. Epub 2024 Aug 26. Br J Haematol. 2024. PMID: 39188028
We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi-responders, and describe distinct transcriptional characteristics and co-occurring mutations of FL harbouring these mutations; reinforcing the growing appr …
We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi-responders, and …
BCOR::CREBBP fusion in malignant neuroepithelial tumor of CNS expands the spectrum of methylation class CNS tumor with BCOR/BCOR(L1)-fusion.
Ebrahimi A, Waha A, Schittenhelm J, Gohla G, Schuhmann MU, Pietsch T. Ebrahimi A, et al. Acta Neuropathol Commun. 2024 Apr 18;12(1):60. doi: 10.1186/s40478-024-01780-5. Acta Neuropathol Commun. 2024. PMID: 38637838 Free PMC article. Review.
Clear diagnostic criteria are still missing for this tumor type, specially that BCOR/BCOR(L1)-fusion is not a consistent finding in these tumors despite being frequent and that none of the Heidelberger classifier versions is able to clearly identify these cases, in particular tum …
Clear diagnostic criteria are still missing for this tumor type, specially that BCOR/BCOR(L1)-fusion is not a consistent finding in these tu …
KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
Vlasevska S, Garcia-Ibanez L, Duval R, Holmes AB, Jahan R, Cai B, Kim A, Mo T, Basso K, Soni RK, Bhagat G, Dalla-Favera R, Pasqualucci L. Vlasevska S, et al. Proc Natl Acad Sci U S A. 2023 Mar 14;120(11):e2218330120. doi: 10.1073/pnas.2218330120. Epub 2023 Mar 9. Proc Natl Acad Sci U S A. 2023. PMID: 36893259 Free PMC article.
Here, we show that combined germinal center (GC)-specific haploinsufficiency of Crebbp and Kmt2d synergizes in vivo to promote the expansion of abnormally polarized GCs, a common preneoplastic event. These enzymes form a biochemical complex on select enhancers/superenhance …
Here, we show that combined germinal center (GC)-specific haploinsufficiency of Crebbp and Kmt2d synergizes in vivo to promote the ex …
Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma.
Mondello P. Mondello P. Leukemia. 2024 Oct;38(10):2087-2089. doi: 10.1038/s41375-024-02355-y. Epub 2024 Jul 19. Leukemia. 2024. PMID: 39030358 Review.
For example, lymphomas harboring the highly recurrent CREBBP mutation show dependency on HDAC3, thus selective inhibition of HDAC3 reversed the epigenetic effects of CREBBP mutation, halted lymphoma growth, and induced MHC class II expression, enabling the T-cells t …
For example, lymphomas harboring the highly recurrent CREBBP mutation show dependency on HDAC3, thus selective inhibition of HDAC3 re …
Comparative Analysis of Drug-like EP300/CREBBP Acetyltransferase Inhibitors.
Crawford MC, Tripu DR, Barritt SA, Jing Y, Gallimore D, Kales SC, Bhanu NV, Xiong Y, Fang Y, Butler KAT, LeClair CA, Coussens NP, Simeonov A, Garcia BA, Dibble CC, Meier JL. Crawford MC, et al. ACS Chem Biol. 2023 Oct 20;18(10):2249-2258. doi: 10.1021/acschembio.3c00293. Epub 2023 Sep 22. ACS Chem Biol. 2023. PMID: 37737090 Free PMC article.
The human acetyltransferase paralogues EP300 and CREBBP are master regulators of lysine acetylation whose activity has been implicated in various cancers. ...Overall, our study demonstrates how knowledge of the relative inhibitor potency can guide the study of EP300/CRE …
The human acetyltransferase paralogues EP300 and CREBBP are master regulators of lysine acetylation whose activity has been implicate …
Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement.
Yang H, Zhang W, Ravanmehr V, Cui G, Bowman K, Chen R, Henderson JM, Lockman S, Rojas E, Wilson A, Parsons S, Mechaly A, Regad L, Haouz A, Flowers CR, Neelapu S, Nastoupil L, Davis RE, Deng Q, Rodrigues-Lima F, Green MR. Yang H, et al. Blood. 2025 Jul 10;146(2):191-205. doi: 10.1182/blood.2024026664. Blood. 2025. PMID: 40090010 Free PMC article.
However, most CREBBP mutations encode amino acid substitutions within the catalytic KAT domain (CREBBP KAT-PM) that retain an inactive protein and have not been extensively characterized. Using CRISPR gene editing and extensive epigenomic characterization of lymphom …
However, most CREBBP mutations encode amino acid substitutions within the catalytic KAT domain (CREBBP KAT-PM) that retain an …
2,560 results